Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Leipzig | OTHER |
| Helios Health Institute GmbH | OTHER |
Not provided
Not provided
Not provided
Not provided
The overall hypothesis is that redo aortic valve replacement (rAVR) is superior to valve-invalve transcatheter aortic valve replacement (ViV-TAVR) for the composite endpoint of freedom from all-cause mortality, all-cause stroke, myocardial infarction, and rehospitalization for heart failure or aortic valve re-intervention at 5 years.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ViV-TAVR | Experimental | The intervention under investigation is transcatheter - preferably transfemoral - ViV-TAVR applied for degenerated surgical aortic bioprostheses with an indication for re-intervention in patients at low-to-intermediate surgical risk. An aortic transcatheter bioprosthesis is implanted into the degenerated surgical aortic bioprosthesis. |
|
| redoAVR | Active Comparator | Surgical redoAVR serves as the control intervention. The patient's degenerated aortic bioprosthesis is replaced using conventional open-heart surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transfemoral transcatheter valve-in-valve implantation | Procedure | The intervention under investigation is transcatheter - preferably transfemoral - ViV-TAVR applied for degenerated surgical aortic bioprostheses with an indication for re-intervention in patients at low-to intermediate surgical risk. An aortic transcatheter bioprosthesis is implanted into the degenerated surgical aortic bioprosthesis. |
| Measure | Description | Time Frame |
|---|---|---|
| The primary endpoint will be a composite endpoint including all-cause mortality, all-cause stroke, myocardial infarction, and re-hospitalization for heart failure or aortic valve reintervention at 5 years. | based on VARC-3 | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Each of the individual components of the primary composite endpoint | based on VARC-3 | 5 years |
| Valve Academic Research Consortium-3 (VARC-3)1-based conduction disturbances and arrhythmia | VARC-3-based conduction disturbances and arrhythmia (qualitative variable; yes or no) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Michael Borger | Contact | 03418650 | Michael.Borger@helios-gesundheit.de | |
| Matthias Raschpichler | Contact | matthias.raschpichler@helios-gesundheit.de |
| Name | Affiliation | Role |
|---|---|---|
| Michael Borger | University Leipzig | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Herzzentrum Leipzig GmbH | Recruiting | Leipzig | Saxony | 04289 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Surgical redo aortic valve replacement | Procedure | Surgical rAVR serves as the control intervention. The patient's degenerated aortic bioprosthesis is replaced using conventional open-heart surgery. |
|
| 5 years |
| Wound and bleeding complications (based on Bleeding Academic Research Consortium class 3b-5) | BARC-based bleeding complications (qualitative ordinal variable; 3b-5) | 5 years |
| New York Heart Association classification III or IV | New York Heart Association classification (qualitative variable; III or IV) | 5 years |
| Health status evaluated by the Kansas City Cardiomyopathy Questionnaire | The KCCQ score, short for Kansas City Cardiomyopathy Questionnaire score, is a disease-specific, patient-reported score used to assess health status in heart failure. It consists of 23 items that assess symptoms, quality of life, and the impact of the disease on physical and social functioning over the past two weeks. Each area is transformed on a scale of 0 to 100, with higher scores indicating better health status. A difference of 5 points is considered clinically relevant, both for improvement and deterioration. | 5 years |
| Health status evaluated by the SF-36 questionnaire | The SF-36 measures 3 aspects of health (functional status, wellbeing, overall evaluation of health) using 8 separate scales. Scores are weighted and transformed into a scale ranging from 0 (greatest possible health restrictions, i.e., severe disability) to 100 (no health restrictions). | 5 years |
| Six-minute walk test | six-minute walk test (quantitative continuous variable) | 5 years |
| Treatment Costs per quality adjusted life year Assessment of Safety | This data will be collected for participating sites of countries in which this data is available. In patient costs will be measured through the collection of hospital billing and resource utilization information. | 5 years |